Related references
Note: Only part of the references are listed.Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice
M. J. Melchers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects With Varying Degrees of Renal Function and Patients With Bacterial Infections
Gurudatt Chandorkar et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Impact of MIC Range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the Ceftolozane In Vivo Pharmacokinetic/Pharmacodynamic Target
A. J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Jason A. Roberts et al.
CLINICAL INFECTIOUS DISEASES (2014)
Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
T. W. Felton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
David J. Farrell et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
In Vivo Activities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice
W. A. Craig et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Monte Carlo Simulations Based on Phase 1 Studies Predict Target Attainment of Ceftobiprole in Nosocomial Pneumonia Patients: a Validation Study
Anouk E. Muller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an In Vitro Infection Model
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane
Brian VanScoy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility
Jason A. Roberts et al.
CRITICAL CARE MEDICINE (2013)
How should we dose antibiotics for pneumonia in the ICU?
Andrew A. Udy et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2013)
Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients
Mario Tumbarello et al.
INTENSIVE CARE MEDICINE (2013)
Pharmacokinetics of Meropenem in Critically Ill Patients With Severe Infections
Lutz Binder et al.
THERAPEUTIC DRUG MONITORING (2013)
Novel Modeling Framework To Guide Design of Optimal Dosing Strategies for β-Lactamase Inhibitors
Pratik Bhagunde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses
Benjamin Miller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
Gurudatt Chandorkar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia
T. P. Lodise et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid Focus on Antibacterial Agents
Keith A. Rodvold et al.
CLINICAL PHARMACOKINETICS (2011)
Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
J. Rello et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Ronald N. Jones
CLINICAL INFECTIOUS DISEASES (2010)
Alveolar concentrations of pipeyacillin/tazobactam administered in continuous infusion to patients with ventilatoy-associated pneumonia
Emmanuel Boselli et al.
CRITICAL CARE MEDICINE (2008)
Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections
Chonghua Li et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia
Morin H. Kollef et al.
CHEST (2006)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia
F de Stoppelaar et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
Share Paper
